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ardiac PET Imaging for the Detection and
onitoring of Coronary Artery Disease and
icrovascular Health
homas H. Schindler, MD,* Heinrich R. Schelbert, MD, PHD,† Alessandra Quercioli, MD,*
asken Dilsizian, MD‡
eneva, Switzerland; Los Angeles, California; and Baltimore, Maryland
ositron emission tomography (PET) myocardial perfusion imaging in concert with tracer-kinetic
odeling affords the assessment of regional myocardial blood flow (MBF) of the left ventricle in
bsolute terms (milliliters per gram per minute). Assessment of MBF both at rest and during various
orms of vasomotor stress provides insight into early and subclinical abnormalities in coronary arterial
ascular function and/or structure, noninvasively. The noninvasive evaluation and quantification of
BF and myocardial flow reserve (MFR) extend the scope of conventional myocardial perfusion
maging from detection of end-stage, advanced, and flow-limiting, epicardial coronary artery disease
CAD) to early stages of atherosclerosis or microvascular dysfunction. Recent studies have shown that
mpaired hyperemic MBF or MFR with PET, with or without accompanying CAD, is predictive of
ncreased relative risk of death or progression of heart failure. Quantitative approaches that measure
BF with PET identify multivessel CAD and offer the opportunity to monitor responses to lifestyle
nd/or risk factor modification and to therapeutic interventions. Whether improvement or normaliza-
ion of hyperemic MBF and/or the MFR will translate to improvement in long-term cardiovascular
utcome remains clinically untested. In the meantime, absolute measures of MBF with PET can be
sed as a surrogate marker for coronary vascular health, and to monitor therapeutic interventions.
lthough the assessment of myocardial perfusion with PET has become an indispensable tool in
ardiac research, it remains underutilized in clinical practice. Individualized, image-guided cardiovas-
ular therapy may likely change this paradigm in the near future. (J Am Coll Cardiol Img 2010;3:
23–40) © 2010 by the American College of Cardiology Foundation
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624espite aggressive medical and interventional
therapies, morbidity and mortality that is
attributable to coronary artery disease
(CAD) remains high (1). There is a striking
ncrease in the prevalence of obesity and type 2
iabetes mellitus in the U.S., which poses a consid-
rable public health concern (2). In particular,
atients with type 2 diabetes mellitus exhibit accel-
rated progression of CAD, which may account for
he increased morbidity and mortality in these
atients (2). Another area of a cardiovascular health
oncern is the expected increase in the longevity of
ost-menopausal women. Unlike pre-menopausal
omen who benefit from endogenous atheropro-
ective estrogens, the cardiovascular risk profile in
ost-menopausal women becomes comparable to
hat of age-matched men, exhibiting higher total
holesterol, low-density lipoprotein cholesterol,
riglycerides, and lower high-density lipoprotein
evels as well as increases in body weight and arterial
hypertension, all known to be proathero-
genic (3). According to the Framingham
Heart Study (4), individuals with a high
cardiovascular risk profile, such as type 2
diabetes mellitus or multiple coronary risk
factors, are at risk for future cardiovascular
events, and are commonly referred for
primary and secondary medical prevention
of CAD (5–7). Individuals with an inter-
mediate cardiovascular risk, however, may
not necessarily be considered for preven-
tive medical interventions and/or life style
modifications.
Apart from standard myocardial perfu-
ion imaging, noninvasive assessment of absolute
yocardial blood flow (MBF) with positron emis-
ion tomography (PET), in milliliters per gram per
inute (ml/g/min), opens opportunities for a com-
rehensive evaluation of asymptomatic and/or early
tages of symptomatic CAD. Assessment of coro-
ary vascular function with PET may further risk
tratify individuals with an intermediate cardiovas-
ular risk (8–10). For example, impaired MBF
esponses to vasomotor stress have been shown to
ndependently predict the development of CAD
11–14). Other possible surrogate markers for sub-
linical CAD include measurements in carotid
ntima-media thickness determined by vascular ul-
rasound (15), or coronary artery calcification
nd/or coronary morphology by multidetector com-
uted tomography (CT) (16,17). Assessment of
unctional abnormalities of the coronary vessels
se
w
rve
ssionith PET may have an advantage over structural mlterations of the arterial wall, as it may identify the
arliest functional stage of the initiation and devel-
pment of the coronary atherosclerotic process be-
ore structural alterations within the arterial wall
ay manifest (18). If CAD-related functional ab-
ormalities of the coronary circulation precede
orphologic changes of the vessels (8,9,19,20),
hen PET could emerge as a promising tool to
etter identify asymptomatic individuals with an
ntermediate or even low cardiovascular risk, who
re likely to benefit from an early initiation or
ntensified medical preventive therapy (8,21).
ethodological Considerations of PET
lowQuantification
ET approaches for the assessment of regional
BF in ml/g/min entails the intravenous injection
f a positron-emitting perfusion tracer, such as
3N-ammonia, 15O-water, or 82Rubidium, and dy-
amic acquisition of images of the radiotracer
assing through the central circulatory system to its
xtraction and retention in the left ventricular
yocardium (Table 1) (19,22,23). Tracer-kinetic
odels (1 to 3 compartments) and operational
quations are then applied to correct for physical
ecay of the radioisotope, partial volume-related
nderestimation of the true myocardial tissue
oncentrations (by assuming a uniform myocar-
ial wall thickness of 1 cm) (24), and spillover of
adioactivity between the left ventricular blood
ool and myocardium (25), to yield regional
BFs in absolute terms, ml/g/min (Figs. 1 and
) (19,26). The relative distribution of the radio-
racer in the myocardium can also be assessed
isually or semiquantitatively (as percentage up-
ake relative to a reference region) from the final
tatic image of the myocardium, obtained from
he last (e.g., 900 s) frame of the PET image
eries (27).
ETMyocardial Perfusion Tracers
he quantification of MBF in absolute units has
een validated for 13N-ammonia and 15O-water
gainst independent microsphere blood flow mea-
urements in animals over a flow range of 0.5 to 5.0
l/g/min (28 –32). In human subjects, 13N-
mmonia and 15O-water provide similar absolute
BF information over a wide range of blood flows
33,34). However, 15O-water images of the myo-
ardium are usually of lower count density, due to
ts short physical and biological half-life in theB B R E V I A T I O N S
N D A C R O N YM S
AD coronary artery disea
PT cold pressor test(ing)
T computed tomography
BFmyocardial blood flo
FRmyocardial flow rese
ET positron emission
omography
PECT single-photon emiyocardium (Table 1), thereby limiting the visual
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625r semiquantitative assessment of regional myo-
ardial perfusion from the static images. Unlike
5O-water static images of the myocardium, 13N-
mmonia yields high-contrast resolution myocar-
ial perfusion images (8,26). The latter is due to
he combination of the high first-pass myocardial
xtraction fraction of 13N-ammonia (near 80%),
rapping of 13N-ammonia in the myocardial cells as
3N-glutamine (long biological half-life), and the
elatively long physical half-life (9.8 min) of the 13N
adiotracer. These properties of 13N-ammonia per-
Figure 1. Serially Acquired Images of a Bolus Transit of 13N-Am
The serially acquired 10-s short-axis images denote the transit of th
tion (from left to right and top to bottom). The initial 2 images illus
quently, the tracer bolus is dispersed into both lungs and returns in
a clearance of the tracer activity from the arterial blood pool into t
(not shown), displays the tracer activity retained in the left ventricu
Table 1. Radiotracers Characteristics and Image Acquisition for
Characteristics 82Rubidium
Half-life 78 s
Extraction fraction* 60%
Cyclotron on-site No
Data acquisition Dynamic, static, gated
Scan duration 6 min
Dose—2D 40–60 mCi
Dose—3D 15–20 mCi
30–40 mCi 3D LSO
Interval between doses 10 min
Image interpretation Yes
Image quality Good
*Extraction fractions are listed for baseline MBF (1 ml/g/min).
2D  2-dimensional; 3D  3-dimensional; LSO  lutetium oxyorthosilicate
tomography.blood pool.it the acquisition of statistically high count
mages of the myocardium by PET with a high
iagnostic quality for the visual and semiquanti-
ative assessment of myocardial perfusion defects
uring stress and rest (Fig. 3) (35). The concur-
ent evaluation of regional MBFs at rest and
uring various forms of vasomotor stress with
3N-ammonia PET and tracer-kinetic models
nables the identification and characterization of
ubclinical and early stages of the coronary ath-
rosclerotic process (8,19,36 –38).
ia Through the Central Circulation
travenously applied radiotracer bolus through the central circula-
e the tracer activity mostly in the right ventricular cavity. Subse-
he left ventricular cavity, as shown in image 3. This is followed by
yocardium (serial 10-s images). The late static image after 18 min
yocardium after the radiotracer has widely disappeared from the
Perfusion Imaging and MBF Quantiﬁcation
13N-Ammonia 15O-Water
9.8 min 2.4 min
80% 95%
Yes Yes
Dynamic, static, gated Dynamic
20 min 5 min
15–25 mCi 40 mCi
15 mCi 10 mCi
30 min 7 min
Yes No
Excellent N/A
F  myocardial blood ﬂow; N/A  not applicable; PET  positron emissionmon
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626In the clinical setting, 13N-ammonia and 82Ru-
idium are the only PET myocardial perfusion
racers that have received U.S. Food and Drug
dministration approval. 82Rubidium for PET
yocardial perfusion imaging is increasingly used in
he clinical routine as it affords the advantages of an
ltra-short 75-s physical half-life and its indepen-
ency of an onsite cyclotron through the availability
f a Strontium-82/Rubidium-82 generator system
al Radiotracer Input Function and Myocardial
e
interest assigned to the left ventricular blood pool and left ven-
ium on the serially acquired images, time activity curves are
ote the alterations in radiotracer activity (y-axis) in the arterial
nts/pixel/second) and in the myocardium (counts/pixel/second) as
e (x-axis). Through ﬁtting of the time activity curves with the
tion formulated from tracer-kinetic models, myocardial blood
ed in absolute units (in ml/g/min). The green line indicates the
er input function, and the red line the myocardial tissue response.
Figure 3. Normal PET Myocardial Perfusion Images (Short Axis)
Note the excellent and good image quality with 13N-ammonia and
15O-water (23) is limited due to the lower count density. Reproduce
PET  positron emission tomography.ith a 4- to 5-week shelf life. However, its rela-
ively lower first-pass extraction and the more
rominent nonlinear myocardial uptake with in-
reasing blood flow, termed “roll-off phenomenon,”
ay lead to relatively lower myocardial contrast
esolution images when compared with 13N-
mmonia (Fig. 3). Despite the known limitations of
ow-dependent extraction fraction of 82Rubidium
or quantification of MBF, recent clinical investi-
ations have reported promising results (39–41).
More recently, F-18–labeled perfusion tracer was
ntroduced for myocardial perfusion imaging with
ET (42,43). The radiotracer has a high first-pass
xtraction fraction of 94%, and is currently being
valuated in phase 1 and 2 clinical studies. The
10-min half-life of F-18 permits its distribution
s a single-unit dose on a daily basis. Moreover,
he longer half-life of F-18 allows the application
f the perfusion agent during treadmill exercise,
ather than with vasodilator stress alone, as is
urrently the case with 82Rubidium PET myocar-
ial perfusion studies.
linical Utility of Quantification of Myocardial
lood Flowwith PET
ssessment of stress-induced myocardial perfusion
efects, with single-photon emission tomography
SPECT) or PET, have been firmly established as
n important diagnostic and prognostic tool for the
valuation of patients with suspected CAD (44,45).
owever, there are distinct limitations with visual
r semiquantitative assessment of regional myocar-
ial perfusion defects that may be overcome by
bsolute quantification with PET. The noninvasive
valuation and quantification of MBF and myo-
ardial flow reserve (MFR) extends the scope of
h Different Positron-Emitting Flow Tracers
bidium (22), respectively, whereas the visual analysis of the static
ith permission from Yoshinaga et al. (22) and Adachi et al. (23).Figure 2. Arteri
Tissue Respons
From regions of
tricular myocard
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627onventional myocardial perfusion imaging from
etection of end-stage, advanced and flow-
imiting, epicardial CAD to early stages of ath-
rosclerosis or microvascular dysfunction, as in:
) the identification of subclinical CAD; 2) the
mproved characterization of the extent and se-
erity of CAD burden; and 3) the identification
f “balanced” reduction of MBF in all vascular
erritories.
dentiﬁcation of subclinical CAD. In symptomatic pa-
ients with known or suspected CAD, SPECT
yocardial perfusion imaging is accurate for iden-
ifying flow-limiting epicardial coronary lesions
46,47). However, vascular disease at the microcir-
ulatory level of the coronary circulation or early
tages of subclinical CAD may remain undetected
ith the standard myocardial perfusion SPECT
maging (32). Patients with subclinical stages of
AD may exhibit either subtle heterogeneity in
elative myocardial uptake of the radiotracer or
omogenously impaired hyperemic blood flow of
he left ventricular myocardium. These same
ndividuals with early stages of CAD-related
unctional and/or structural alterations of the
oronary arterial wall have been shown to be at
ncreased long-term risk for cardiovascular events
12,13). By quantifying hyperemic MBF or MFR
n absolute terms, PET can identify early func-
ional abnormalities of the coronary circulation,
hich may be a precursor of the ensuing CAD
rocess (8,13,48 –50).
mproved characterization of CAD burden. Decreased
egional radiotracer uptake on standard SPECT
r PET myocardial perfusion imaging during
yperemic flow are a consequence of flow-
imiting epicardial coronary artery lesions. Visual
r semiquantitative interpretation of regional ra-
iotracer uptake is in relative terms, where the
yocardial region with the highest radiotracer
ptake is considered as the “normal reference
egion.” However, in patients with multivessel
AD, the designated normal reference region
ay in fact be abnormal as well, but relative to
he other vascular territories it is the least hy-
operfused myocardial region (51–53). In such
atients, the concurrent absolute MBF or MFR as-
essment with PET may uncover, not only the most
emodynamically significant culprit lesion, but also
he true extent of ischemic burden in the left ventric-
lar myocardium, in a multivessel territory, which
ncludes the normal reference region (53,54). Thus,
he combined assessment of “relative” and “absolute”
yocardial perfusion imaging provides information, dot only on flow-limiting isolated epicardial le-
ions, but also on the downstream functional
onsequences of anatomically intermediate
nd/or sequential coronary artery lesions, or con-
inuous tapering of coronary artery vessel due to
iffuse atherosclerosis (55–57).
dentiﬁcation of “balanced” reduction of MBF in all
ascular territories. The assessment of only “rela-
ive” distribution of the radiotracer uptake in the
eft ventricular myocardium with standard myo-
ardial perfusion imaging may also fail to identify
balanced” reduction of MBF in all vascular
erritories. In such patients, the relative distribu-
ion of myocardial perfusion may be homog-
nously reduced in the entire left ventricular
yocardium without visually discernable regional
efects that characterize CAD patients (52).
onsequently, only about 10% of patients with
evere 3-vessel CAD or significant stenosis of the
eft main coronary artery (50%) may be detected by
tress-induced regional perfusion defects on SPECT
mages (51,58). The addition of gated SPECT func-
ional data may improve the identification of patients
ith severe 3-vessel CAD or left main disease to 25%
59). A more direct assessment of absolute MBF of
FR with PET may unmask balanced ischemic
urden of the left ventricular myocardium in all 3
ajor coronary artery vascular territories. The latter,
owever, should always be confirmed by a peak stress
ransient ischemic cavity dilation of the left ventricle
uring maximal vasomotor stress on gated PET im-
ges (60,61).
valuation of Flow-Limiting Epicardial Lesions:
dvantages of PET
he high spatial and contrast resolution of the
hoton attenuation–free images of PET in concert
ith superior properties of 13N-ammonia or 82Ru-
idium as MBF tracers offers several advantages of
ET over SPECT for detection of CAD. PET
ameras identify paired photons (511 keV of energy
ach) produced by the positron annihilation effect
Fig. 4). The paired 511 keV travel in the opposite
irection at a 180° angle from each other. There-
ore, positron decay can be localized without colli-
ation, as used for SPECT, but with the use of the
rinciple of coincidence detection. As PET cameras
o not necessitate collimators, these systems have a
uch higher sensitivity than do SPECT cameras,
esulting in a higher spatial resolution in the range
f 4 to 7 mm (62). The principle of coincidence
etection in concert with the superior properties of
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628BF tracers such as 13N-ammonia with a better
xtraction fraction at higher flows has also led to an
ncrease in contrast resolution (Table 1) (Fig. 3).
oth the higher spatial and contrast resolution of
ET perfusion studies may allow the identification
f regional differences in radiotracer uptake during
harmacologically induced hyperemia (Fig. 5).
hese properties of PET perfusion imaging may
xplain, at least in part, the higher sensitivity in
he identification of flow-limiting epicardial le-
ions as compared with SPECT imaging with
01Thallium or 99mTc-labeled perfusion tracers
19). The average sensitivity and specificity of
yocardial perfusion PET or PET/CT scanners
or detecting 50% or 70% luminal narrowing
n coronary angiography is reported to be in the
ean of 92% and 90%, respectively (63– 65). The
ncrease in specificity of PET perfusion imaging
s compared with SPECT (66,67) can be related
o the robust attenuation correction of the emis-
ion data using the transmission source (68Ge
otating rod source or CT) (Fig. 6).
oncordance and Discordance Between Coronary
rtery Narrowing andMyocardial
erfusion Abnormality
uantitative coronary angiography (QCA) is com-
only accepted as a “gold standard” for the assess-
ent of the epicardial coronary artery diameter and
uminal narrowing (68). When epicardial luminal
arrowing exceeds 50%, it is commonly paralleled
y a decrease in MBF reserve and manifestation of
yocardial ischemia (69–72). It should be kept in
Figure 4. Principles of Coincidence Detection
A positron () emitted from the atomic nucleus of 13N travels thro
with an electron (e). Since the e and  are antiparticles, they u
generation of 2 photons traveling in opposite directions at a 180° a
are identiﬁed as coincidences in the detector ring of the PET camerind, however, that despite the well-described dnverse relationship between severity of coronary
rtery stenosis and MFR, a high degree of variabil-
ty in the individual flow responses may exist, in
articular when the coronary artery luminal narrow-
ng is of intermediate severity (Fig. 7) (56,69,71). In
he case of CT-determined luminal narrowing,
tress-induced regional myocardial perfusion de-
ects as determined with 201ThaIlium SPECT were
een in 33% of regions with 60% to 70% stenosis,
4% of regions with 70% to 80% stenosis, and 86%
f regions with 80% stenosis (73). Beyond an
daptive vasodilation of the coronary arteriolar ves-
els to compensate increases in epicardial resistance
ue to significant epicardial narrowing of the arte-
ial lumen (56,57), other possible explanations for
he discordances in the literature include an over-
stimation of the severity of coronary artery stenosis
y angiography and/or a lack of absolute regional
BF assessment with the perfusion data. Nonethe-
ess, a relatively preserved regional hyperemic MBF
r MFR may in fact prevent the manifestation of
tress-induced myocardial ischemia even in the
resence of intermediate to severe epicardial artery
esions. Thus, medical therapy that targets and
mproves the function of the coronary artery circu-
ation or its vasodilator capacity, e.g., HMG-CoA
eductase or angiotensin-converting enzyme inhib-
tors, may prevent or even regress clinically manifest
yocardial ischemia in patients with CAD (74,75).
his possibility is supported by the recent suba-
alysis of the COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug
valuation) trial (45). Medical treatment of car-
iovascular risk factors in patients with SPECT-
a medium and loses energy and slows down until it interacts
rgo a process called “annihilation.” The latter manifests in the
from each other with an energy of 511 keV each. These photons
ET  positron emission tomography.ugh
nde
ngleetermined regional myocardial perfusion defects
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629ver a 1-year follow-up targeting the improve-
ent of MBF reserve was associated with a
ignificant reduction in ischemic burden and a favor-
ble clinical outcome. Another factor that is likely to
revent the manifestation of stress-induced regional
schemia is the induction of collaterals by the hypoxic
timulus, which strive to balance reduced flow in-
reases during times of increased metabolic demand in
yocardial regions subtended by flow-limiting epicar-
Figure 5. 13N-Ammonia PET/CT and Coronary Angiography in th
(A) Stress and rest 13N-ammonia PET images of the heart in short-a
62-year-old type 2 diabetic patient. The stress images demonstrate
ing to the inferolateral region of the left ventricle, which is complet
phy shows an occluded marginal branch of the left circumﬂex coro
anterior descending coronary artery (arrow) and a 50% stenosis in
ease; CT  computed tomography; PET  positron emission tomogial lesions (76). ossessment of Hyperemic MBF, MFR, and Relative
adiotracer Content
he ability of PET to assess regional MBF at rest
nd during vasomotor stress, concurrently, affords
bsolute quantification of regional hyperemic
BFs and MFR, by which, apart from the “culprit
esion” causing the stress-induced regional myocar-
ial perfusion defect, the hemodynamic significance
valuation of CAD
vertical long-axis, and horizontal long-axis slices are shown from a
oderately decreased perfusion defect involving the lateral extend-
reversible on rest images. (B) Corresponding coronary angiogra-
artery (arrow), with diffuse 50% stenosis of the proximal left
mid right coronary artery (not shown). CAD  coronary artery dis-
hy.e E
xis,
a m
ely
nary
thef each epicardial lesion can be identified in all 3
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630ascular territories. The optimal threshold values of
yperemic MBFs or MFR to identify flow-limiting
picardial lesions, however, is dependent on the
ET methodology and radiotracer applied for the
BF quantification (19,36,56). Among patients
Attenuation Correction of PET Emission Data Using CT
ial image from a PET/CT 13N-ammonia study without attenuation
Myocardial radiotracer distribution shows relatively higher 13N-
ptake in the lateral wall with evidence of lung uptake. (B) The
ing transmission attenuation map demonstrates the lung and
ons. (C) After the application of attenuation correction, the myo-
-ammonia uptake demonstrates a more homogenous myocardial
with relatively higher uptake in the septum compared with the
l and decreased background activity. Abbreviations as in Figure 5.ith known or suspected CAD undergoing phar- aacologic vasodilation with 13N-ammonia PET,
he diagnostic value of hyperemic MBF, MFR, and
he relative radiotracer content (millicuries per mil-
iliter) for detecting 70% flow-limiting epicardial
esions was the highest, when a hyperemic MBF
hreshold value of 1.85 ml/g/min was applied
67). The receiver-operator characteristic analysis of
ET parameters in the evaluation of the diagnostic
ccuracy of CAD demonstrated the highest value of
.90 for adenosine-stimulated absolute hyperemic
BF, 0.86 for MFR, and 0.69 for 13N-ammonia
elative uptake (77,78). Similar findings were re-
ently reported by other investigators (79,80). Us-
ng 15O-water, a threshold of pharmacologically
nduced hyperemic MBFs of 2.5 ml/g/min was
hown to be most accurate in the identification of
picardial lesions of 50% diameter stenosis (79).
nother investigation using quantitative 82Rubid-
um PET demonstrated a nonlinear decrease in
yperemic MBFs as the severity of coronary artery
tenosis increased (80). It appeared that the MFR
ould differentiate epicardial lesions between 70%
o 80% from those with 50% to 69% stenosis.
Hyperemic MBFs during pharmacologic vasodi-
ation may also be diminished due to coronary
icrovascular dysfunction in patients with or with-
ut focal CAD lesions on coronary angiography but
ith multiple cardiovascular risk factors (49,81,82).
urthermore, a grey zone may exist in patients with
picardial lesions 50% and a MBF reserve be-
ween 2.0 and 2.5, where the significance of down-
tream consequences of a focal epicardial lesion may
emain uncertain. Overall, adding PET-determined
egional hyperemic MBFs and MFR to standard
yocardial perfusion imaging certainly increases
he sensitivity in the identification of each flow-
imiting epicardial lesion in multivessel disease but
t the expensive of a lower specificity (83,84).
hether this approach may play a role in the future
or revascularization planning with percutaneous
nterventions or coronary artery bypass surgery, or
oth (so-called hybrid interventions) in patients
ith multivessel CAD remains uncertain and re-
uires clinical validation. Current clinical applica-
ion of myocardial perfusion imaging with PET is
imed at differentiating normal vasomotor stress
esponse from hemodynamically significant coro-
ary artery lesions (stress-induced regional perfu-
ion defect) (Fig. 8) and subclinical CAD (Fig. 9).
mong individuals with high cardiovascular risk
ho exhibit reduced hyperemic MBF and MFR on
ET but without significant epicardial coronaryFigure 6.
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631ention and lifestyle modifications may apply.
owever, in view of the relatively low specificity of
bnormal MBF reserve (69,85), current application
nd interpretation of MBF reserve with PET have
o be placed in the proper clinical context with
nderlying coronary anatomy and cardiovascular
isk factors (Fig. 9).
ssessment of Subclinical Stages of CAD
nd Prognosis
n patients exhibiting normal SPECT or PET
yocardial perfusion studies by relative radiotracer
ontent, the assessment of impaired hyperemic
BFs and MFR by absolute quantitative PET
49,81,86) may further identify individuals who are
t increased risk for cardiovascular events
12,13,87). For example, in insulin-resistant indi-
iduals with normal stress-rest myocardial perfusion
ET images, concurrent MBF quantification has
ncovered abnormalities in endothelium-related
BF responses to cold pressor testing (CPT),
hereas hyperemic flows during pharmacologic va-
odilation were preserved (88). These observations
upport the contention that initial stages of the
ascular injury may involve only the endothelium
89–91), whereas more advanced stages of coronary
isk factor states, such as increases in oxidative stress
urden, may lead to an impairment in smooth
uscle cell vasodilator function (92). Indeed, coro-
ary circulatory dysfunction in individuals with
0
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Figure 7. MBF and Coronary Vasodilator Reserve in Relation to
(A) At rest (green circles), there is no relationship between myocardia
(red circles), there is an inverse relationship between hyperemic MBFs
ﬂow reserve (MFR  hyperemic MBF / resting MBF) shows a similar in
intermediate severity, there was a relatively high variability in MFR. No
the MFR due to microvascular disease may be comparable to those in
relationship between MFR and percentage stenosis persists when the
tion coefﬁcient r  0.77, root mean square error  0.37, p  0.00001)
from Di Carli et al. (71).ncreasing body weight may progress from an im- rairment in endothelium-dependent coronary flow
esponse to CPT, in the early stages of overweight,
o an impairment of the predominantly
ndothelium-independent hyperemic flows during
ipyridamole stimulation in the late stages of obe-
ity (49). Similarly, in patients with insulin resis-
ance, progressive worsening of functional abnor-
alities of endothelium-dependent vasomotion
ay occur with increasing severity of insulin resis-
ance and carbohydrate intolerance, with attenua-
ion of the total vasodilator capacity occurring in
he later stages, in patients with clinical type 2
iabetes mellitus (70). An inverse relationship be-
ween MFR and plasma glucose levels has been
hown in patients with type 2 diabetes mellitus,
roviding first evidence of direct adverse effect of
aised plasma glucose concentration on diabetes-
elated coronary vasculopathy (88).
In individuals with increased cardiovascular risk,
he assessment of MBF response to CPT may
rovide the earliest insight into coronary endothe-
ial (dys)function as a precursor to progression of
AD and its prognostic consequence (8,18,50). In
atients with normal coronary angiograms, but with
ardiovascular risk factors, attenuation of PET-
easured and endothelium-related MBF responses
o sympathetic stimulation with CPT and its MFR
ere associated with a higher risk for cardiac events
s compared with those with normal flow increases
12). Moreover, the incidence of cardiovascular
vents increased with the extent of abnormal flow
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632eyond reduced MFR, stress-induced myocardial
erfusion defects is also an independent predictor of
ardiovascular outcome (9). However, adding the
FR information to the stress 13N-ammonia per-
usion PET data allowed further risk stratification,
dentifying a “warranty” period of event-free sur-
ival of 3 years when both stress myocardial perfu-
ion and MFR data were normal. Contrarily, when
oth stress myocardial perfusion and MFR data
ere abnormal, impaired MFR provided incremen-
al information to the stress 13N-ammonia perfu-
ion PET data for predicting adverse outcomes. It is
Figure 8. 13N-Ammonia PET in the Evaluation of CAD
(A) Myocardial perfusion study with 13N-ammonia PET during dipyrida
tension and type 2 diabetes mellitus. On stress images, there is a mod
anteroseptal, and apical regions of the left ventricle, which becomes re
rior regions. (B) Stress and rest integrated PET/CT images of the left ve
image allows an accurate coregistration of relatively low spatial resolut
anatomic signal of the CT-contrast image. For direct comparison, 13N-a
delineation of the left ventricular cavity and myocardial wall (left pane
during dipyridamole stimulation, at rest, and the difference between s
blood ﬂow (MBF) (upper panel) and within the 3 major vascular territo
S. Nekolla). The summarized quantitative data (lower panel), suggests
artery (LAD) territory, but also in the right coronary artery (RCA), and le
angiography in this patient demonstrated a proximal occlusion of the
sequential 50% to 60% lesions in the RCA (right panel) (53). Abbreviatmportant to highlight the prognostic differences Petween stress myocardial perfusion SPECT or
ET studies and PET-assessment of coronary cir-
ulatory dysfunction. Whereas the presence of
tress-induced myocardial perfusion defects on
PECT or PET is predictive of cardiovascular
vents during a shorter follow-up period of time
e.g., 1 year), PET assessment of coronary circula-
ory dysfunction in patients without flow-limiting
picardial coronary artery lesions commonly pre-
icted future cardiovascular events (e.g., after 2 to 3
ears) (12,13,27,87,93,94). Consequently, the as-
essment of coronary circulatory dysfunction with
stimulation and at rest in a 61-year-old patient with arterial hyper-
ly decreased perfusion defect involving the mid-to-distal anterior,
ible on the rest images. Uptake is preserved in the lateral and infe-
ular myocardium are shown (middle panel). Integrated PET/CT
of the 13N-ammonia perfusion signal of PET with the high-resolution
onia PET perfusion images (right panel) and CT-contrast images with
e shown prior to integration. (C) Polar maps of 13N-ammonia PET
and rest are displayed in terms of absolute regional myocardial
(lower panel) are shown (Munich Heart Program software package,
stinct impairment of the MFR not only in the left anterior descending
ircumﬂex artery (LCX) vascular territories (MFR 2.0). (D) Coronary
, 80% stenosis in the proximal segments of the LCX (left panel), and
as in Figures 3 and 5.mole
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633actors, who are at risk of developing CAD and its
therothrombotic sequelae.
Beyond its incremental value in individuals with
AD or subclinical stages of CAD, impairment in
oronary circulatory function has also been shown
o be predictive of future cardiovascular outcome in
atients without underlying CAD, such as those
ith hypertrophic cardiomyopathy and idiopathic
ardiomyopathy (10,95). Such clinical observations
mphasize the importance of integrating coronary
irculatory function as an index of the overall stress
urden imposed by various coronary risk factors on
he arterial wall (8,96).
eproducibility of MBFs During Vasomotor Stress
f impaired coronary circulatory function is a pre-
ictor of future cardiovascular events, then medical
nterventions or lifestyle modifications, that im-
rove or normalize the coronary circulatory func-
ion, would be expected to improve patient out-
ome. In view of this evolving concept, PET
easurements of MBF responses to cold exposure
nd/or to pharmacologic vasodilation are being
pplied increasingly in the clinical setting in order
o detect and monitor the effects of medical therapy
nd/or lifestyle modifications on coronary circula-
ory function (8,9,20,78). The use of serial PET
yocardial blood flow studies to monitor progres-
ion or regression of coronary circulatory (dys)func-
ion necessitates establishing the reproducibility of
Stress-rest Myocar
Normal Perfusion
MBF Quantification
MFR 2.0-2.5MFR >2.5 MFR <2.0
BorderlineNormal Abnormal
+
+
– ++
Coronary Circulatory Function
Preventive Medical Intervention
Figure 9. Algorithm for the Integration of PET Perfusion Images
Algorithm for the integration of PET myocardial perfusion imaging
quantiﬁcation in individuals with suspected or an intermediate risk
tion or preventive medical therapy is shown. Abbreviations as in Figepeated PET MBF measurement (8,97). The re-roducibility of MBF to CPT and measurement
rror of MBF at rest and during various forms of
asomotor stress along with hemodynamic and
iologic factors, that may contribute to the variabil-
ty in these repeat MBF measurements, are shown
n Table 2 (97–102). The reproducibility of hyper-
mic MBF increases during pharmacologic vasodi-
 Perfusion PET
MFR 2.0-2.5MFR >2.5 MFR <2.0
+
+
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Abnormal Perfusion
Coronary Angiography:
Epicardial Lesions 50-70% Stenosis
MBF Quantification
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Figure 10. PET-Determined Coronary Endothelial Vasoreactivity
and Prognosis
Kaplan-Meier analyses in patients with cardiovascular risk factors an
coronary angiograms undergoing assessment of myocardial blood ﬂ
response to cold pressor test (CPT) with positron emission tomogra
Attenuation of PET-measured and endothelium-related MBF respon
pathetic stimulation with cold pressor testing are associated with a
for cardiac events (during long-term follow-up) as compared with t
normal ﬂow increases; normal (%∆MBF 40%), impaired (%∆MBF 
40%), and decreased (%∆MBF 0%). Reproduced with permissiondial
an
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phy (PET).
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634ation and bicycle exercise using 13N-ammonia,
5O-labeled water or 82Rubidium with PET are
easonable and in the range of 4 to 15% (99,103–
05). Also when CPT-related MBFs were mea-
ured with 15O-labeled water on a 1-day protocol,
he MBFs appeared to be reproducible within 27%
106). In a more comprehensive investigation (97),
he hemodynamic and endothelium-related MBF
esponses to CPT from rest (MBF), as measured
ith 13N-ammonia and PET, were demonstrated
o be not only highly reproducible in short-term
1-day protocol), but also in long-term (2- to
-weeks protocol) within a range of 10% (Table 2).
n this regard, the range of measurement errors, as
ndicated by the standard error of the estimate
SEE) from the Pearson correlation coefficient (r)
f the least-square regression for the endothelium-
elated MBF to CPT determined with 13N-
mmonia PET, was observed to be 0.09 ml/g/min
or short-term and 0.17 ml/g/min for long-term
epeat measurements (Table 2). According to these
alues of SEE, changes in MBF to CPT in serial
edical intervention and/or lifestyle modification
tudies are likely to exceed this range of SEE (97).
pplying the mean difference and the correspond-
ng standard deviation (SD) of repeat MBF assess-
ent in Table 2, one can derive the sample size of
study population that would be needed to suffi-
iently power a serial MBF PET study. For exam-
modynamics at Measurements 1 (m  1) and 2 (m  2) on the Sa
m  1 CV m  2 CV
0.67 0.19 0.29 0.66 0.15 0.22
0.88 0.21 0.24 0.85 0.20 0.23
0.21 0.17 0.79 0.19 0.16 0.83
n) 61 7 0.12 62 9 0.13
116 12 0.11 120 15 0.12
71 7 0.10 73 6 0.08
7,113 1,161 0.16 7,349 1,157 0.16
CPT
n) 68 8 0.12 67 7 0.11
148 22 0.15 152 22 0.15
86 11 0.13 87 12 0.14
9,982 1,798 0.18 10160 1456 0.14
2,869 1,666 0.58 2,811 1,300 0.46
paired t test; p  NS for intragroup comparisons between coefﬁcients of variation
ing; DBP  diastolic blood pressure; MBF  myocardial blood ﬂow; RPP  rate–le, using the longitudinal mean difference and the sorresponding SD of the MBF to CPT of 0.08 
.05 ml/g/min in the short-term and of 0.19 0.10
l/g/min in the long-term, at a 5% significance
evel with a power of 87%, a sample size of 14 and
2 individuals would be needed for serial 13N-
mmonia PET flow studies in order to identify
ossible intervention-related, statistically significant
lterations in MBF responses to CPT (97). Another
seful statistical parameter commonly referred to in
he interpretation of reproducibility data is the repeat-
bility coefficient as suggested by Bland and Altman
107), which denotes the agreement between repeat
easurements. Conversely, the repeatability coeffi-
ient can also be used as an index for direct compar-
son of the precision of MBF measurements between
ET flow studies that have utilized different radio-
racers (97). For example, the repeatability coefficient
or short- and long-term reproducibility measure-
ents of MBF to CPT with 13N-ammonia PET
ere lower than those for hyperemic MBF increases
eported previously (99,104,108).
onitoring Therapy
ccording to the Framingham Heart Study (4),
ndividuals with a high cardiovascular risk profile,
uch as type 2 diabetes mellitus or multiple coronary
isk factors, are at risk for future cardiovascular
vents, and are commonly referred for primary and
Day and Measurement 3 (m  3) After 2 Weeks for All Study
m  3 CV
Absolute Mean
Difference
m  12
Absolute Mean
Difference
m  13
0.63 0.18 0.28 0.09 0.10 0.10 0.10
0.82 0.21 0.13 0.11 0.09 0.14 0.10
0.19 0.14 0.41 0.08 0.05 0.19 0.10
61 9 0.16 2.5 2.2 7.1 5.0
115 13 0.11 5.5 7.6 6.6 5.6
69 8 0.11 3.0 2.6* 5.5 5.3
,936 986 0.14 430 445 789 691
67 9 0.14 3.5 2.4 5.8 5.1
149 23 0.16 5.8 10 8.3 11
85 13 0.15 2.7 2.1 8.5 6.9
,935 1,259 0.18 724 543 1,470 1,011
,999 1,740 0.58 762 517 1,046 857
) 1 to 3 by analysis of variance (Levene test). Reproduced with permission from
ure product; SBP  systolic blood pressure.Table 2. MBF and He me
Participants (N  20)
MBF in ml/g/min
At rest
During CPT
∆ Change to CPT
Hemodynamics at rest
Heart rate (beats/mi
SBP (mm Hg)
DBP (mm Hg)
RPP (mm Hg/min) 6
Hemodynamics during
Heart rate (beats/mi
SBP (mm Hg)
DBP (mm Hg)
RPP (mm Hg/min) 9
∆RPP (mm Hg/min) 2
*p  0.05 for difference by (CV
Schindler et al. (97).econdary medical prevention of CAD (5–7). Indi-
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635iduals with an intermediate cardiovascular risk,
owever, may not necessarily be considered for
reventive medical interventions and/or life style
odifications. In this regard, assessment of coro-
ary vascular or circulatory function with PET may
urther risk stratify these individuals with an inter-
ediate cardiovascular risk (8–10). Other possible
urrogate markers for subclinical CAD include
easurements in carotid intima-media thickness
etermined by vascular ultrasound (15), or coronary
rtery calcification and/or coronary morphology by
ultidetector CT (16,17). Assessment of functional
bnormalities of the coronary vessels with PET may
ave an advantage over structural alterations of the
rterial wall, as it may identify the earliest func-
ional stage of the initiation and development of the
oronary atherosclerotic process before structural
lterations within the arterial wall may manifest
18). If CAD-related functional abnormalities of
he coronary circulation precede morphologic
hanges of the vessels (8,9,19,20), then PET could
merge as a promising tool to better identify asymp-
omatic individuals with an intermediate or even
ow cardiovascular risk, who are likely to benefit
rom an early initiation or intensified medical pre-
entive therapy (8,21). Further, given the pivotal
ole of functional abnormalities of the coronary
irculation in the development and progression of
therosclerosis, an improvement or even restoration
f PET-determined coronary circulatory dysfunc-
ion in response to various forms of vasomotor
0
-0.1
p=0.45
-0.2
0.1
0.2
0.3
0.4
0.5
0.6
p<0.02
Base FU Base FU
Figure 11. Hormone Replacement and PET-Determined Coronar
Effect of hormone replacement therapy (HRT) on coronary endothe
cardiovascular risk factors. The endothelium-related change in myoc
baseline (Base) and follow-up (FU) among different groups are show
the ∆MBF response to CPT was generally maintained, whereas in th
CPT. Interestingly, the ∆MBF to CPT in post-menopausal women wh
those women who had never been on HRT, suggesting perhaps a “
duced with permission from Schindler et al. (48). PET  positron emissitress by a variety of preventive medical interven-
ions, such as angiotensin-converting enzyme in-
ibitors (75), beta-hydroxymethylglutaryl coen-
yme A reductase inhibitors (109), hormone
eplacement therapy in post-menopausal women
48,89), insulin-sensitizing thiazolodinedione in
nsulin-resistant individuals (88), euglycemic con-
rol in diabetes, and physical exercise (110,111), has
ecome a primary therapeutic strategy for pre-
ention of the atherosclerotic process. Notably,
ome preliminary observations in the assessment
f vascular function of the peripheral circulation
ay strongly suggest that a normalization of
ndothelium-dependent vascular function by pre-
entive medical intervention may indeed lead to an
mproved cardiovascular outcome (112,113).
mong patients presenting with acute coronary
yndrome and treated with standard medical ther-
py, the group that normalized their endothelial
unction (assessed at the forearm) was paralleled by
n event-free survival, but not in those patients who
id not normalize their endothelial function (112).
n post-menopausal hypertensive women, an im-
rovement in brachial artery flow-mediated
endothelium-dependent) vasodilation after instal-
ation of aggressive antihypertensive therapy re-
ulted in an improved clinical outcome (113). In
iew of these preliminary findings, PET assessment
f MBF responses to vasomotor stress may prove as
n unique tool to noninvasively identify and char-
cterize coronary circulatory dysfunction, as func-
p<0.001
Base FU
HRT
No HRT
HRT at Baseline
but not FU
dothelial Vasoreactivity in Post-Menopausal Women
ysfunction in post-menopausal women with medically treated
ial blood ﬂow (∆MBF) from rest to cold pressor testing (CPT) at
n post-menopausal women with HRT at baseline and follow-up,
omen without HRT, there was a signiﬁcant decrease in ∆MBF to
ad discontinued HRT during follow-up was even worse than in
und” phenomenon on coronary endothelial (dys)function. Repro-y En
lial d
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636ional precursor of CAD, and to monitor the
uccess of effects of pharmacologic interventions or
ifestyle modification on the functioning of the
oronary circulation in asymptomatic cardiovascular
isk individuals or in patients with clinically mani-
est CAD (8,114). Using PET measurements of
BF in response to CPT to evaluate coronary
ndothelial function, a divergent response after
edical control of blood pressures with the angio-
ensin II receptor blocker olmesartan and with the
alcium antagonist amlodipine was observed (116).
hereas angiotensin II receptor blocker improved
oronary endothelial function, no such beneficial
ffect was observed for the calcium antagonist
mlodipine. Most likely, specific antioxidative ef-
ects of angiotensin II receptor blocker accounted
or the improvement in coronary endothelial func-
ion and, thereby, mediated vascular resistance
gainst the development of CAD in these hyper-
ensive patients. PET flow studies also contributed
o unmask beneficial effects of hormone replace-
ent therapy with medically treated cardiovascular
isk factors (48). As it was observed, hormone
eplacement therapy with estrogen alone or in
oncert with a progesterone in post-menopausal
omen, in addition to standard preventive medical
ntervention of traditional cardiovascular risk fac-
ors, contributed to preserve the functional integrity
f the coronary endothelium (Fig. 11). Conceptu-
lly, a normal function of the coronary circulation
n cardiovascular risk individuals in fact should
xert numerous vasoprotective effects against the
evelopment of CAD-related structural disease, pre-
ominantly mediated through the release of athero-
rotective and endothelium-derived nitric oxide (8). If
his holds true, then a normalization of coronary
irculatory function in cardiovascular risk individuals
hould prevent the manifestation and/or progression
f a CAD process. Indeed, as recent investigations
uggest (115), an improvement of endothelium-and the young at heart. N Engl
J Med 2007;356:2639–41. tors. N Engl J Medellitus after 1-year follow-up in response to glucose
owering treatment with metformin and/or glyburide
ay mediate direct preventive effects on the progres-
ion of epicardial structural disease. Although these
reliminary observations of PET flow studies strongly
upport the evolving concept that improvement in
oronary circulatory function in asymptomatic cardio-
ascular risk individuals or in patients with clinically
anifest CAD may lead to an improved clinical
utcome, it remains to be tested in further prospective,
arge-scale clinical trials.
onclusions
ssessment of stress-induced myocardial perfusion
efects have been firmly established as an important
iagnostic and prognostic tool for the evaluation of
atients with suspected CAD. Cardiac PET in con-
unction with tracer-kinetic modeling for 13N-
mmonia, 15O-water, or 82Rubidium affords the as-
essment of regional MBF of the left ventricle in
bsolute units in ml/g/min, which adds a new dimen-
ion to the noninvasive evaluation of the CAD pro-
ess. By assessing MBFs and the MFR noninvasively,
ET may identify early functional and/or structural
bnormalities of the coronary artery circulation before
ts progression to symptomatic CAD ensues. In par-
icular, the identification and characterization of the
asodilator capacity and endothelial reactivity of the
oronary circulation may guide decisions for medical
herapy as well as monitor the effects of pharmacologic
nterventions, risk factor modification, or lifestyle
hanges. The aim of image-guided and personalized
reventive vascular medicine may soon be attainable
ith PET technology.
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